Taken together, these results demonstrate that RdB/IL12/shVEGF can induce higher expression of IL-12, downregulate VEGF expression more efficiently, and elicit more potent cancer cell killing effect than either single gene-expressing RdB/IL12 or RdB/shVEGF, making it a promising platform for oncolytic Ad-mediated cancer immunogene therapy. This evidence concerns the gene VEGFA and cancer.